Risk of breast cancer (women only), prostate cancer (men only) and colon cancer in the calcium channel blocker (CCB) cohort compared to the non-CCB antihypertensive (AHT) drugs cohort
| Breast cancer (women only) | Prostate cancer (men only) | Colon cancer | ||||
|---|---|---|---|---|---|---|
| CCB cohort | AHT cohort | CCB cohort | AHT cohort | CCB cohort | AHT cohort | |
| Cancer rates (crude per 1000 person-years) | 3.05 | 2.32 | 4.10 | 2.50 | 1.41 | 0.92 |
| Number of cancers | 1397 | 1194 | 1753 | 1014 | 1249 | 849 |
| Number of person-years | 457 417 | 514 400 | 427 654 | 404 833 | 885 070 | 919 233 |
| Crude HR (95% CI) | 1.33 (1.23 to 1.43) | 1.00 (reference) | 1.64 (1.52 to 1.78) | 1.00 (reference) | 1.54 (1.41 to 1.68) | 1.00 (reference) |
| Adjusted HR (95% CI) | 0.95 (0.87 to 1.04) | 1.00 (reference) | 1.07 (0.98 to 1.16) | 1.00 (reference) | 0.89 (0.81 to 0.98)* | 1.00 (reference) |
*p=0.02. HR obtained from multivariate Cox proportional hazard analyses including age at index date, gender, smoking status, body mass index, alcohol consumption, diagnoses of diabetes, hypertension, arrhythmia, angina or heart failure, and use of statins or aspirin.